Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma Meeting Abstract

  

Authors:	Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; Schwartz, G. K.; Rosen, N.; Chapman, P. B.
Abstract Title:	Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma
Meeting Title:	104th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	73
Issue:	8 Suppl.
Meeting Dates:	2013 Apr 6-10
Meeting Location:	Washington, DC
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2013-04-15
Language:	English
ACCESSION:	BCI:BCI201400247043
DOI:	10.1158/1538-7445.am2013-2284
PROVIDER:	biosis
Notes:	Meeting Abstract: 2284 -- 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- Washington, DC, USA -- April 06 -10, 2013 -- Amer Assoc Canc Res -- 0 -- Source: Biosis

https://synapse.mskcc.org/synapse/works/has_related_data_chk/52600